Page last updated: 2024-11-12
km-233
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
KM-233: used for the treatment of high-grade glioma; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10248110 |
| CHEMBL ID | 119592 |
| SCHEMBL ID | 14447597 |
| MeSH ID | M0501137 |
Synonyms (25)
| Synonym |
|---|
| (6ar,10ar)-6,6,9-trimethyl-3-(1-methyl-1-phenyl-ethyl)-6a,7,10,10a-tetrahydro-6h-benzo[c]chromen-1-ol |
| 6,6,9-trimethyl-3-(2-phenylpropan-2-yl)-6a,7,10,10a-tetrahydro-6h-benzo[c]chromen-1-ol |
| bdbm50133546 |
| (6ar,10ar)-6,6,9-trimethyl-3-(2-phenylpropan-2-yl)-6a,7,10,10a-tetrahydro-6h-benzo[c]chromen-1-ol |
| km-233 |
| CHEMBL119592 , |
| 628263-22-9 |
| SCHEMBL14447597 |
| Q6333245 |
| km 233 |
| (6ar,10ar)-6,6,9-trimethyl-3-(2-phenylpropan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
| nsc-792739 |
| nsc792739 |
| km233 |
| ymv7s3c3b7 , |
| baj4486bwx , |
| 797793-15-8 |
| HY-123410 |
| CS-0082626 |
| 6h-dibenzo[b,d]pyran-1-ol, 6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-(1-methyl-1-phenylethyl)-, (6ar,10ar)-rel- |
| 6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-(1-methyl-1-phenylethyl)-6h-dibenzo[b,d]pyran-1-ol, (6ar,10ar)-rel- |
| 6h-dibenzo[b,d]pyran-1-ol, 6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-(1-methyl-1-phenylethyl)-, (6ar,10ar)- |
| (6ar,10ar)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-(1-methyl-1-phenylethyl)-6h-dibenzo[b,d]pyran-1-ol |
| rel-(6ar,10ar)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-(1-methyl-1-phenylethyl)-6h-dibenzo[b,d]pyran-1-ol |
| AKOS040745948 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The cytotoxic effects of KM-233 against human glioma cells in vitro occur as early as two hours after administration, and dosing of KM-233 can be cycled without compromising cytotoxic efficacy and while improving safety." | ( Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. Boehm, P; Divi, MK; Duntsch, C; Jones, T; Krishnamurthy, M; Moore, BM; Sills, A; Wood, G; Zhou, Q, 2006) | 0.88 |
| " Dose escalation studies in the orthotopic model using U87MG cells revealed an 80 % reduction in tumor size after 12 mg/kg daily dosing for 20 days." | ( Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. Abidi, AH; Allison, P; Bigner, DD; Duntsch, C; Elberger, AJ; Guan, P; Gurley, SN; Keir, ST; Kosanke, SD; Moore, BM; Robertson, JH, 2012) | 0.61 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | Ki | 0.0009 | 0.0005 | 0.0220 | 0.0520 | AID311038 |
| Cannabinoid receptor 1 | Homo sapiens (human) | Ki | 0.0123 | 0.0001 | 0.5077 | 9.6000 | AID311037; AID406561; AID414286; AID416355; AID49314 |
| Cannabinoid receptor 2 | Homo sapiens (human) | Ki | 0.0009 | 0.0000 | 0.4156 | 10.0000 | AID311038; AID406562; AID414287; AID416356; AID49845 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (58)
Molecular Functions (10)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| phospholipid transporter activity | Cholesteryl ester transfer protein | Homo sapiens (human) |
| lipid binding | Cholesteryl ester transfer protein | Homo sapiens (human) |
| cholesterol binding | Cholesteryl ester transfer protein | Homo sapiens (human) |
| triglyceride binding | Cholesteryl ester transfer protein | Homo sapiens (human) |
| phosphatidylcholine binding | Cholesteryl ester transfer protein | Homo sapiens (human) |
| cholesterol transfer activity | Cholesteryl ester transfer protein | Homo sapiens (human) |
| cannabinoid receptor activity | Cannabinoid receptor 1 | Homo sapiens (human) |
| protein binding | Cannabinoid receptor 1 | Homo sapiens (human) |
| identical protein binding | Cannabinoid receptor 1 | Homo sapiens (human) |
| G protein-coupled receptor activity | Cannabinoid receptor 1 | Homo sapiens (human) |
| protein binding | Cannabinoid receptor 2 | Homo sapiens (human) |
| cannabinoid receptor activity | Cannabinoid receptor 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (18)
Bioassays (19)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID416355 | Binding affinity to CB1 receptor | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations. |
| AID49845 | Binding affinity towards Cannabinoid receptor 2 using CP-55940 as radioligand in HEK293 EBNA cells | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20 | Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids. |
| AID311038 | Binding affinity to CB2 receptor | 2007 | Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12 | The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2. |
| AID416356 | Binding affinity to CB2 receptor | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations. |
| AID414287 | Binding affinity to human CB2 receptor transfected in HEK293 cells | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands. |
| AID49314 | Binding affinity towards Cannabinoid receptor 1 using CP-55940 as radioligand in HEK293 EBNA cells | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20 | Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids. |
| AID414286 | Binding affinity to human CB1 receptor transfected in HEK293 cells | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands. |
| AID406568 | Cytotoxicity against human DBTRG-O5MG cells assessed as cell death after 18 hrs | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. |
| AID406564 | Cytotoxicity against human U87 cells by side flank model relative to control | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. |
| AID311037 | Binding affinity to CB1 receptor | 2007 | Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12 | The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2. |
| AID406561 | Displacement of [3H]CP-55940 from human CB1 receptor expressed in HEK293 cells | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. |
| AID49327 | Ratio of binding affinity towards cannabinoid receptor-1 (CB1) to that of cannabinoid receptor-2 (CB2) | 2003 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20 | Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids. |
| AID406569 | Cytotoxicity against human MT310 cells assessed as cell death after 18 hrs | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. |
| AID414288 | Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6 | Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands. |
| AID406565 | Cytotoxicity against human U87MG cells assessed as cell death after 18 hrs | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. |
| AID406567 | Cytotoxicity against human LN229 cells assessed as cell death after 18 hrs | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. |
| AID406566 | Cytotoxicity against human T98G cells assessed as cell death after 18 hrs | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. |
| AID406562 | Displacement of [3H]CP-55940 from human CB2 receptor expressed in CHO-K1 cells | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. |
| AID406563 | Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 24.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.43) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||